Histidine‐containing dipeptides reduce central obesity and improve glycaemic outcomes: A systematic review and meta‐analysis of randomized controlled trials
Abstract
Supplementation with histidine‐containing dipeptides has been shown to improve obesity and glycaemic outcomes in animal and human studies. We conducted a systematic review and meta‐analysis of randomized controlled trials to examine these effects. El...
Supplementation with histidine‐containing dipeptides has been shown to improve obesity and glycaemic outcomes in animal and human studies. We conducted a systematic review and meta‐analysis of randomized controlled trials to examine these effects. Electronic databases were searched investigating the effects of histidine‐containing dipeptides supplementation on anthropometric and glycaemic outcomes. Meta‐analyses were performed using random‐effects models to calculate the weighted mean difference and 95% confidence interval. There were 30 studies for the systematic review and 23 studies pooled for meta‐analysis. Histidine‐containing dipeptide groups had a lower waist circumference (WMD [95% CI] = −3.53 cm [−5.65, −1.41], p = 0.001) and HbA1c level (WMD [95% CI] = −0.76% (8.5 mmol/mol) [−1.29% (14.3 mmol/mol), −0.24% (2.8 mmol/mol)], p = 0.004) at follow‐up compared with controls. In sensitivity analyses of studies with low risk of bias, waist circumference, HbA1c, and fasting glucose levels (WMD [95% CI] = −0.63 mmol/L [−1.09, −0.18], p = 0.006) were significantly lower in intervention groups versus controls. There was also a trend toward lower fat mass (p = 0.09), insulin resistance (p = 0.07), and higher insulin secretion (p = 0.06) in intervention versus control groups. Supplementation with histidine‐containing dipeptides may reduce central obesity and improve glycaemic outcomes. Further studies exploring histidine‐containing dipeptide use in obesity and diabetes prevention and treatment are warranted.